Items tagged with Scientific research
New treatment principle for tuberculosis activates the body's own defence system (post)
According to a new study from Karolinska Institutet which is being published in the journal Autophagy, the body's own defence system can be strengthened with existing medicines used for treating tuberculosis. The results suggest a new treatment principle for infectious diseases that can strengthen the effect of traditional antibiotic treatments and reduce the risk of developing a resistance.
Brown University to help Ghana build HIV, TB research capacity (post)
With $1.45 million over five years from the Fogarty International Center of the National Institutes of Health, a pair of Brown University professors will work with colleagues in Ghana to build the research capacity needed to address the deadly co-epidemics of HIV and tuberculosis.
TB researchers earn NIH grant to study potential for shortening treatment course (post)
Stop Jeff North, Ph.D., if you’ve heard this one before: an indole-based drug and a tuberculosis protein meet in a laboratory. There’s a brief interaction, then the drug skates merrily away while the protein is nowhere to be found.
Otago’s international TB research efforts gain major support (post)
University of Otago researchers have been awarded $450,000 for research into the genetics of drug-resistant tuberculosis (TB) in Indonesia and Myanmar.
A novel toxin – and the first ever found – for a deadly pathogen, M. tuberculosis (post)
Despite 132 years of study, no toxin had ever been found for the deadly pathogen Mycobacterium tuberculosis, which infects 9 million people a year and kills more than 1 million.
Powering off TB: New electron transport gene is a potential drug target (post)
The U.S. Food and Drug Administration recently approved the first new drug to fight tuberculosis (TB) in more than 40 years, but treatment still takes six months, 200 pills and leaves 40 percent of patients uncured. Thus, new targets are needed. Today in ACS Central Science, researchers report they have identified one such target -- a gene that allows the disease to camp out in human immune cells, and is thus essential for the organism's proliferation.
New publication highlights CPTR’s work on Hollow Fiber System Model for TB (post)
The achievements and ongoing efforts of CPTR’s work on the Hollow Fiber System Model for TB (HFS-TB) are detailed in a new supplement published in the Clinical Infectious Diseases journal. The supplement includes an editorial by EMA on its qualification of this tool to reliably assess the potential efficacy of new drugs and combination regimens, an editorial by FDA supporting the use of this tool in drug development and articles co-authored by members of CPTR’s Preclinical and Clinical Sciences Workgroup. It can be read online here.
IDRI, Wellcome Trust team for tuberculosis vaccine trial in South Africa (post)
SEATTLE, September 17, 2015 -- Today, the Infectious Disease Research Institute (IDRI) and Wellcome Trust announce the start of a Phase 2a trial in South Africa of IDRI's tuberculosis (TB) vaccine candidate, which has been shown to both prevent and treat TB in preclinical studies in animal models. The Wellcome Trust awarded IDRI a $5.8 million/ £3.8 million grant to clinically assess the ability of IDRI's vaccine candidate to reduce TB recurrence after treatment. Even after successfully completing an anti-TB treatment regimen, patients may succumb to TB again, thereby threatening TB control programs by promoting spread and drug resistance. Prior Phase 1 clinical trials have shown that IDRI's TB vaccine candidate boosts immune responses that may protect against TB recurrence.
The novel vaccine candidate against tuberculosis, MTBVAC, initiates Phase 1B clinical trial (post)
The clinical trial will be conducted by South African Tuberculosis Vaccine Initiative (SATVI).
Biofabri, biotechnology company focusing on human health vaccines, will sponsor the Phase 1B clinical trial.
CID supplement: Advances in tuberculosis research: A blueprint for opportunities (post)
The supplement provides an update on the status of Mycobacterium tuberculosis research for drugs, vaccines, and diagnostics, and the intersection of these disciplines to better understand tuberculosis disease pathogenesis.
Page 11 of 74 · Total posts: 0
←First 10 11 12 Last→